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Our Thanks to Hoechst-Roussel Pharmaceuticals Inc. 
We recogllize with appreciatioll Hoechst-RolISsci Phal1lJaccllticais Illc. for 
pledging Sllpp0/1 to the Elldol/I/ /l c/lt F,md for T he J oumal of Investigative 
Dermatology, which will be I/sed to SIIPPO,t the growth alld colltillll ed 
sl/ccess 'if the joII,." al. T his sIIpport "'ill certaillly strellgthell alld pe'petllate 
the partncrship bet",een the pharlll acelltical illdllStry alld basic alld clillical 
investigators ill CIItall cO llS biology. 
In This Issue . • 
Jackie R. Bickenbach 
I¥e saillte Hoechst-Rollssel Pharlllaceuticals Illc. for their colltriblltioll to 
the E lldo ll' lII ellt Fll lld alld for their cOlltilllled sllpport of clillical alld ;,wes-
tigatille derlllatology. 
EJ. O'Ketje, Chapel Hill, NC 
A New Molecular Assay with High Sensitivity Provides Evidence for Systemic Involvement in Early 
Cutaneous T-Cell Lymphoma 
Veelken et al (p. 889) have modified a recently developed assay, a 
polymerase chain reaction (PCR)-based RNAse protection assay 
(PCR/RPA) that may be useful in the staging of cutaneous T -cell 
lymphoma (CTCL). T lus assay is based on the rapid detection of 
clonal T -cell receptor gamma chain gene rearrangements. Previ-
ously, diagnostic techniques involved Southern blotting of genomic 
DNA isolated from biopsy specimens. With this method, lymphoid 
malignancies could be detected as a clonal excess of a specific type 
of antigen receptor gene rcarrangcmcnt over polyclonal rcarrange-
ments. The in troduction of amplification of rearranged antigen 
receptor gcnes by the PCR allowed ana lysis of very small samples. 
Using PCR ampli fication in addition to RNAse protection (PCRI 
RPA) , Veclken and co-workers arc able to detect a single malig-
nant cell in 105 nOrl1lal bone marrow ceLIs , making this diagnostic 
assay tenfold more sensitive. In this study, the authors test w hether 
uSillg tlus scnsitive molecular assay improves staging of a solid 
lymphoid malignancy. T hey compare thrce m ethods for the mo-
lecular detection oflymphomatous involvement in biopsies, includ-
ing a variety of involved aJld uninvolved areas , fi·om patients with 
CTCL including one patien t with stagc 1 A . They report that 
PCR/RPA was able to detect malignant cell s in 100% of the 
biopsies, w hereas the other two m ethods failed to detect malignant 
cells in about 40%. T hus, PCR/ RPA may bc useful in detecting 
early recurrence during clinical remission. 
Autoantibodies Agairlst Desmoglein 1 Cause Blisters in Pemphigus Foliaceus 
Amagai ct al (p. 895) provide new evidence that aJltibodies to the 
desmoso mal cadherin desmoglein 1 (Dsgl) are pathogenic in 
pemphigus foliaccus. Both pemphigus vulgaris and pemplugus 
foliaceus involve circulating IgG antibod.ies that bind to stratified 
epithelia. In addition, antibodies from pemplugus patients can 
induce the disease phenotype (i.e., blisters) in skin in o rgan culture 
and in neonatal mice. cDNA cloning has revealed that ilie antigens 
are members of tlle desmoglein subf.1mily of the cadherin super-
gene fami ly, and these cadherins have been designated desmoglein 
3 (Dsg3) in pemphigus vulgaris and desmoglein 1 (Dsgl) in 
pemphigus foliaceus. 
In previous studies, the authors have found that recombinant 
pemphigus vulgaris antigen expressed in bacteria was recognized by 
60% of sera from patients, and autoantibodies recognizing the 
expressed protein were able to produce blisters in neonatal mice. 
Using a similar approach to pemphigus fo liaceus, the authors 
engineered a secreted form of Dsgl and expressed the protein in a 
baculovirus vector. Their results demonstrate that antibodies spe-
cificaJly directed against the Dsgl extracellular domain cause 
characteristic blistering at the granular level of tlle epidermis in 
neonata l mice, a model for the disease. In addition, the baculopro-
tein harvested fi·om conditioned medium was able to absorb 
immunoreactivity agalllst the keratinocyte cell surface in 100% of 
pemphigus foliaceus sera tested. These data provide additional md 
more direct evidence that anti-Dsgl antibodies are the causative 
agent in pemphigus folia ceus and show that the pathogenic aJlti-
bodies are directed against tll e extracellular domain. 
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